Clinical trials: Atherosclerosis Occlusive Disease, active
Asthma, Atherosclerosis
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Background: Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation.
- Conditions
- Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance
- Trial name
- NCT01143480
- Where
- United States
- Volunteers
- 725 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction…
- Trial name
- REVEAL (NCT01252953)
- Testing
- Anacetrapib
- Where
- United Kingdom
- Volunteers
- 30,449 people
- Sponsor
- University of Oxford
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
The ROAMM-EHR Study
In recent years, mobile health (mHealth) apps have promised improved monitoring of health conditions to improve clinical outcomes.
- Trial name
- ROAMM-EHR (NCT06263322)
- Testing
- Actionable remotely generated health data, Non-Actionable remotely generated health data
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Cardiovascular Disease
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C.
- Trial name
- AZURE-LDL (NCT07000123)
- Testing
- AZD0780
- Where
- 404 sites in United States, Argentina and 20 more
- Volunteers
- 3,103 people
- Sponsor
- AstraZeneca
Atherosclerosis, Cardiovascular Diseases
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- Trial name
- ACCLAIM-CTA (NCT07613294)
- Testing
- Lepodisiran
- Where
- 57 sites in United States, Australia and 5 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Critical Limb Ischemia, Peripheral Arterial Disease
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to peripheral…
- Trial name
- NCT05854641
- Testing
- Stempeucel®
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- Cell Biopeutics Resources Sdn Bhd
Peripheral Arterial Disease
Peripheral Arterial Disease Biomarkers
The study aims to determine how expression levels of biomarkers for peripheral arterial disease change over time in response to exercise therapy, surgical or endovascular intervention, and whether they can be used to predict…
- Trial name
- PADBIRD (NCT06373302)
- Volunteers
- 100 people
- Sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
Stroke, Transient Ischemic Attack
Angiogenic Markers in Cerebrovascular Disease (ANFIS)
Intracranial atherosclerosis (ICAS) is the most common cause of stroke worldwide. It carries a worse prognosis than other stroke etiologies, with an annual rate of recurrent stroke and death of 15% despite intensive medical…
- Conditions
- Stroke, Transient Ischemic Attack, Atherosclerosis, Intracranial Arterial Stenosis
- Trial name
- ANFIS (NCT04240119)
- Testing
- According to current clinical care standards
- Volunteers
- 300 people
- Sponsor
- Cedars-Sinai Medical Center
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Stroke, Acute, Stroke, Ischemic
Carotid Artery Stenting During Endovascular Treatment of Acute Stroke
Rationale: Approximately 20% of the patients with acute ischemic stroke due to an intracranial large vessel occlusion (LVO) has a high-grade stenosis in the ipsilateral cervical carotid artery.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Carotid Stenosis, Carotid Atherosclerosis
- Trial name
- CASES (NCT06511089)
- Testing
- carotid artery stenting during EVT, no carotid artery stenting during EVT
- Where
- Netherlands
- Volunteers
- 600 people
- Sponsor
- University Medical Center Groningen
Peripheral Artery Disease, Diabetes Mellitus
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
The aim of this clinical study is to 1) establish a healthy database for nuclear perfusion imaging of the lower extremities and 2) assess the prognostic value of radiotracer-based perfusion imaging for predicting clinical…
- Conditions
- Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
- Trial name
- NCT03622359
- Testing
- SPECT/CT perfusion imaging, PET/CT perfusion imaging
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Peripheral Arterial Disease
Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion.
- Trial name
- NCT07049120
- Testing
- ZENFLEX Pro™ Peripheral Drug-eluting Stent System
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Melanoma, Atherosclerosis
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
This study is a prospective observational study evaluating the natural history of coronary plaque burden in participants with melanoma treated with ICI. The study will be conducted at various sites across Australia.
- Trial name
- SOCRATES (NCT05180942)
- Where
- 12 sites in Australia
- Volunteers
- 130 people
- Sponsor
- Monash University
Carotid Stenosis
Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control
Cerebrovascular accident (CVA) constitutes a major health public problem. This represents the second cardiovascular death cause. CVA is ischemic in 80% of cases.
- Trial name
- ACABII (NCT02748941)
- Testing
- HITS quantification, Ultrasound examinations, High Resolution MRI
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Hospices Civils de Lyon
Chronic Limb Threatening Ischemia
Vessel Recoil in Specific CLTI Populations
Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene.
- Trial name
- NCT07465627
- Testing
- Vessel recoil measurement 15 minutes post final treatment (angiographically)
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Graz
Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
VITUS Post-Market Registry
To collect post marketing surveillance data on consecutive patients with peripheral arterial occlusive disease (PAOD) intended to be or treated by the VITUS peripheral drug-coated dilatation catheter when used according to the…
- Trial name
- NCT06832631
- Testing
- Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 283 people
- Sponsor
- OrbusNeich
Peripheral Artery Disease, Peripheral Vascular Diseases
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
Peripheral artery disease (PAD) is associated with elevated oxidative stress, and oxidative stress has been implicated as the cause of reduced endothelial reactivity in individuals with PAD.
- Conditions
- Peripheral Artery Disease, Peripheral Vascular Diseases, Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
- Trial name
- NCT06319339
- Testing
- Vumerity
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.